Pulse.

a daily field guide to health research that matters

◆ Console

‹ Fri · 13 Nov 2026
Standard addition

Allogeneic hematopoietic stem cell transplantation is associated with improved long-term survival and molecular MRD clearance in KMT2A-altered AML

Patients with high-risk leukemia who achieve molecular clearance after stem-cell transplant show better survival, offering hope that this measure can guide treatment decisions.

This cohort examined molecular residual disease and transplant outcomes in 155 people with high-risk KMT2A-altered acute myeloid leukemia. Molecular negativity predicted better survival, while transplantation was associated with a much higher rate of sustained molecular clearance.

What the study was

Study design
Single-center retrospective cohort with multivariable and time-dependent survival analyses
Population
Adolescent and adult patients with KMT2A-altered acute myeloid leukemia
Sample size
155
Category
Treatment Innovation
Maturity
Exploratory
Journal
Annals of medicine

Why it surfaced

The study addresses a high-unmet-need leukemia subtype with clinically actionable residual-disease findings, but its retrospective single-center design limits certainty.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.